Antitumor activity and safety of pembrolizumab in patients (pts) with advanced squamous cell carcinoma of the head and neck (SCCHN): Preliminary results from KEYNOTE-012 expansion cohort.

Tanguy Y. Seiwert, Laura Q.M. Chow, Dung T. Le et al.|Journal of Clinical Oncology|2015

Cited by 103